NasdaqGS - Nasdaq Real Time Price USD

BioCryst Pharmaceuticals, Inc. (BCRX)

10.08

-0.19

(-1.85%)

At close: May 7 at 4:00:00 PM EDT

10.08

0.00

(0.00%)

Pre-Market: 5:11:06 AM EDT

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

We recently published a list of Why These 10 Firms Soared on Monday. In this article, we are going to take a look at where BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stands against other Monday’s best performers. The stock market kicked off the trading week on a negative note as investors sold off on a new round of […]

Insider Monkey 2 days ago

BCRX
-1.85%

^GSPC
BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

BioCryst Pharmaceuticals Inc (BCRX) reports robust Q1 results with increased revenue guidance and strategic debt reduction, setting the stage for early profitability.

GuruFocus.com 2 days ago

BCRX
-1.85%
Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call

Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 2 days ago

BCRX
-1.85%
BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

BioCryst (BCRX) delivered earnings and revenue surprises of 100% and 14.97%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 days ago

BCRX
-1.85%
BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

—Q1 2025 ORLADEYO net revenue of $134.2 million (+51 percent y-o-y)— —Full year 2025 ORLADEYO revenue guidance increased to $580 million to $600 million— —Company now expects to be profitable for full year 2025, a year ahead of schedule— —Company pays down $75 million of debt; saves approximately $23.5 million over life of loan— —NDA submitted for ORLADEYO oral granules for children with HAE aged 2-11— —U.S. IND open for BCX17725 for Netherton syndrome— RESEARCH TRIANGLE PARK, N.C., May 05, 2025

GlobeNewswire 2 days ago

BCRX
-1.85%
High Growth Tech Stocks To Watch In The US May 2025

The U.S. stock market is experiencing a notable upswing, with the S&P 500 on track for its longest winning streak since 2004, buoyed by strong employment data and potential trade talks between the U.S. and China. In this environment of optimism and recovery, identifying high-growth tech stocks requires a focus on companies that demonstrate resilience in volatile conditions, adaptability to policy changes, and robust financial health amidst evolving economic landscapes.

Simply Wall St. 5 days ago

MIRM

BCRX
-1.85%

TRVG
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted seven newly-hired employees restricted stock units (RSUs) covering an aggregate of 48,000 shares of BioCryst common stock. The RSUs were granted as of May 1, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing R

GlobeNewswire 5 days ago

BCRX
-1.85%
BioCryst Appoints Steve Frank to Board of Directors

RESEARCH TRIANGLE PARK, N.C., May 01, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed healthcare investment banking leader Steve Frank to its board of directors. Mr. Frank serves as chairman of global healthcare investment banking at J.P. Morgan. He was previously global group head of worldwide healthcare investment banking at Bear Stearns before it was acquired by J.P. Morgan in 2008. Mr. Frank is a trusted corporate advisor,

GlobeNewswire 6 days ago

BCRX
-1.85%
Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Inotiv (NOTV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 7 days ago

NOTV

BCRX
-1.85%
BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., April 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: Citizens Life Sciences Conference in New York on Thursday, May 8, 2025, at 9:00 a.m. ET. Bank of America 2025 Health Care Conference in Las Vegas on Wednesday, May 14, 2025, at 1:40 p.m. ET. 2025 RBC Capital Markets Global Healthcare Conference in New York on Wednesday, May 21, 2025, at 3:05 p.m. ET. Links t

GlobeNewswire 7 days ago

BCRX
-1.85%
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 9 days ago

BCRX
-1.85%
BioCryst to Report First Quarter 2025 Financial Results on May 5

RESEARCH TRIANGLE PARK, N.C., April 21, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2025 financial results on Monday, May 5, 2025. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing 1-844-481-2942 for domestic callers and 1-412-317-1866 for international callers. A live

GlobeNewswire 16 days ago

BCRX
-1.85%
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks 27 days ago

BCRX
-1.85%
BioCryst to Present at Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025, at 9:30 a.m. ET. Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com. About BioCryst Pharmaceuticals BioCryst Pharmaceuticals is a global biotech

GlobeNewswire last month

BCRX
-1.85%
High Growth Tech Stocks In The US Market With Promising Potential

The United States market has remained flat over the past week but has seen an 8.5% increase over the past year, with earnings projected to grow by 14% annually. In this context, identifying high-growth tech stocks involves looking for companies that are well-positioned to capitalize on technological advancements and market trends, offering promising potential in a dynamic economic landscape.

Simply Wall St. last month

BCRX
-1.85%

PGY

PGYWW
Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be...

Simply Wall St. last month

BCRX
-1.85%
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) stands against the other small-cap stocks. The S&P 500 index has reached its all-time highs, achieving returns of over 20% for the second consecutive year […]

Insider Monkey 2 months ago

BCRX
-1.85%

^RUT

^GSPC
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for BioCryst (BCRX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks 2 months ago

BCRX
-1.85%
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for BioCryst (BCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 2 months ago

BCRX
-1.85%
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 84.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

BCRX
-1.85%

Performance Overview

Return	BCRX	S&P 500 (^GSPC)
YTD	+34.04%	-4.26%
1-Year	+91.63%	+8.55%
3-Year	+10.89%	+36.57%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioCryst Pharmaceuticals, Inc. (BCRX)

Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday

BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ...

Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call

BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

High Growth Tech Stocks To Watch In The US May 2025

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Appoints Steve Frank to Board of Directors

Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

BioCryst to Report First Quarter 2025 Financial Results on May 5

How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry

BioCryst to Present at Upcoming Investor Conference

High Growth Tech Stocks In The US Market With Promising Potential

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know

Performance Overview